Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SANUWAVE Health (SNWV) Notes Payables (2016 - 2024)

SANUWAVE Health has reported Notes Payables over the past 14 years, most recently at $7.7 million for Q3 2024.

  • Quarterly Notes Payables rose 206.81% to $7.7 million in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $7.7 million through Sep 2024, up 206.81% year-over-year, with the annual reading at $7.1 million for FY2023, 57.46% down from the prior year.
  • Notes Payables was $7.7 million for Q3 2024 at SANUWAVE Health, up from $6.4 million in the prior quarter.
  • Over five years, Notes Payables peaked at $17.0 million in Q1 2023 and troughed at $226000.0 in Q1 2022.
  • The 5-year median for Notes Payables is $2.0 million (2021), against an average of $4.8 million.
  • Year-over-year, Notes Payables crashed 93.98% in 2020 and then soared 7401.33% in 2023.
  • A 5-year view of Notes Payables shows it stood at $321000.0 in 2020, then surged by 397.2% to $1.6 million in 2021, then skyrocketed by 947.18% to $16.7 million in 2022, then tumbled by 57.46% to $7.1 million in 2023, then increased by 7.68% to $7.7 million in 2024.
  • Per Business Quant, the three most recent readings for SNWV's Notes Payables are $7.7 million (Q3 2024), $6.4 million (Q2 2024), and $7.5 million (Q1 2024).